18F-FDG PET/CT在预测可切除食管鳞状细胞癌新辅助PD-1阻断联合化疗病理反应中的作用
该事后分析纳入58例接受两周期卡瑞利珠单抗联合化疗的可切除食管鳞状细胞癌患者,于基线及术前行18F-FDG PET/CT,评估代谢参数与病理反应的关系。结果显示19例(32.8%)达病理完全缓解,pCR组复查时SUVmax、SUVmean、SUVTBR、TLG及MTV均显著低于非pCR组,且TLG与MTV降幅更大。复查SUVmax等参数对原发灶pCR有良好预测价值,阳性淋巴结SUVmax高于阴性,阴性预测能力达98.6%,界值1.4。
要点
- 58例可切除ESCC接受两周期卡瑞利珠单抗联合化疗,19例(32.8%)达pCR。
- 复查时pCR组SUVmax、SUVmean、SUVTBR、TLG、MTV均显著低于非pCR组。
- 阳性淋巴结SUVmax高于阴性,阴性预测能力98.6%,界值1.4。
核心结论
- 18F-FDG PET/CT参数对可切除ESCC新辅助免疫联合化疗后pCR具有良好预测性能。
研究设计与样本
- 事后分析,纳入58例接受两周期卡瑞利珠单抗联合化疗的可切除ESCC患者。
- 于基线(scan-1)及免疫化疗后术前(scan-2)行18F-FDG PET/CT,评估代谢参数与病理反应的关系。
- 试验注册号ChiCTR2000028900,注册日期2020年1月6日。
主要发现
- 19例(32.8%,19/58)达pCR,39例(67.2%,39/58)为非pCR。
- scan-2时pCR组SUVmax、SUVmean、SUVTBR、TLG及MTV均显著低于非pCR组。
- 同一患者scan-2较scan-1的TLG与MTV降幅在pCR组显著高于非pCR组。
- ROC分析中scan-2的SUVmax、SUVmean、SUVTBR、TLG及MTV对原发灶pCR显示良好预测价值。
- scan-2阳性淋巴结SUVmax高于阴性淋巴结,界值1.4时阴性预测能力98.6%。
关键数值与推荐
- pCR定义为两剂卡瑞利珠单抗联合化疗后病理完全缓解,19/58例(32.8%)达pCR。
- scan-2参数预测原发灶pCR的ROC分析显示良好预测价值。
- 淋巴结SUVmax界值1.4,阴性预测能力98.6%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Accurate assessment of residual disease of tumor and lymph nodes after neoadjuvant immunochemotherapy is crucial in the active surveillance for patients with pathological complete response (pCR) and the optimal extent of lymphadenectomy for patients with non-pCR. This post hoc analysis aimed to evaluate the performance of 18F-FDG PET/CT to predict the pathological response to neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma (ESCC). METHODS: Fifty-eight resectable ESCC patients received two cycles of camrelizumab in combination with chemotherapy and were enrolled in the final analysis. The 18F-FDG PET/CT scans were acquired at baseline (scan-1) and after immunochemotherapy but prior to surgery (scan-2). Maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), tumor-to-blood pool SUVmax ratio (SUVTBR), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were evaluated for their association with the pathological response to immunochemotherapy. RESULTS: Nineteen patients (32.8%, 19/58) had pCR and thirty-nine patients (67.2%, 39/58) had non-pCR after two doses of camrelizumab and chemotherapy. At scan-2, the SUVmax, SUVmean, SUVTBR, TLG, and MTV were significantly lower in pCR than in non-pCR patients. Decrease in TLG and MTV between scan-2 and scan-1 of the same patient was significantly higher in the pCR than in the non-pCR group. In the receiver operating characteristic curve analysis, SUVmax, SUVmean, SUVTBR, TLG, and MTV in scan-2 showed excellent predictive value for the pCR of primary tumors. Furthermore, SUVmax in scan-2 were higher in positive lymph nodes than in negative ones, suggesting a high negative predictive ability (98.6%) with a cut-off value at 1.4. CONCLUSION: The parameters of 18F-FDG PET/CT have the excellent performance for predicting pCR after the combined neoadjuvant immunochemotherapy in resectable ESCC. TRIAL REGISTRATION: ChiCTR2000028900. Registered on January 6, 2020.
引用
- Wang X, Yang W, Zhou Q, et al. The role of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant PD-1 blockade in combination with chemotherapy for resectable esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2022. PMID: 35732974. doi:10.1007/s00259-022-05872-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。